147 related articles for article (PubMed ID: 26067885)
1. Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening.
Goede SL; Kuntz KM; van Ballegooijen M; Knudsen AB; Lansdorp-Vogelaar I; Tangka FK; Howard DH; Chin J; Zauber AG; Seeff LC
Med Care; 2015 Jul; 53(7):630-8. PubMed ID: 26067885
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer screening differential costs for younger versus older Americans.
Ladabaum U; Phillips KA
Am J Prev Med; 2006 May; 30(5):378-84. PubMed ID: 16627125
[TBL] [Abstract][Full Text] [Related]
3. Estimating the impact of insurance expansion on colorectal cancer and related costs in North Carolina: A population-level simulation analysis.
Hassmiller Lich K; O'Leary MC; Nambiar S; Townsley RM; Mayorga ME; Hicklin K; Frerichs L; Shafer PR; Davis MM; Wheeler SB
Prev Med; 2019 Dec; 129S():105847. PubMed ID: 31666187
[TBL] [Abstract][Full Text] [Related]
4. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
[TBL] [Abstract][Full Text] [Related]
5. Endoscopist-directed propofol administration versus anesthesiologist assistance for colorectal cancer screening: a cost-effectiveness analysis.
Hassan C; Rex DK; Cooper GS; Benamouzig R
Endoscopy; 2012 May; 44(5):456-64. PubMed ID: 22531982
[TBL] [Abstract][Full Text] [Related]
6. Productivity savings from colorectal cancer prevention and control strategies.
Bradley CJ; Lansdorp-Vogelaar I; Yabroff KR; Dahman B; Mariotto A; Feuer EJ; Brown ML
Am J Prev Med; 2011 Aug; 41(2):e5-e14. PubMed ID: 21767717
[TBL] [Abstract][Full Text] [Related]
7. Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.
Buskermolen M; Gini A; Naber SK; Toes-Zoutendijk E; de Koning HJ; Lansdorp-Vogelaar I
Med Decis Making; 2018 Nov; 38(8):917-929. PubMed ID: 30343626
[TBL] [Abstract][Full Text] [Related]
8. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
[TBL] [Abstract][Full Text] [Related]
9. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand.
Ladabaum U; Song K
Gastroenterology; 2005 Oct; 129(4):1151-62. PubMed ID: 16230069
[TBL] [Abstract][Full Text] [Related]
10. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes.
Sweet A; Lee D; Gairy K; Phiri D; Reason T; Lock K
Appl Health Econ Health Policy; 2011; 9(1):51-64. PubMed ID: 21174482
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model.
Idigoras I; Arrospide A; Portillo I; Arana-Arri E; Martínez-Indart L; Mar J; de Koning HJ; Lastra R; Soto-Gordoa M; van der Meulen M; Lansdorp-Vogelaar I
BMC Public Health; 2017 Aug; 18(1):78. PubMed ID: 28764731
[TBL] [Abstract][Full Text] [Related]
12. The estimated costs and savings of medical nutrition therapy: the Medicare population.
Sheils JF; Rubin R; Stapleton DC
J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
[TBL] [Abstract][Full Text] [Related]
13. Loss of efficacy and cost-effectiveness when screening colonoscopy is performed by nongastroenterologists.
Hassan C; Rex DK; Zullo A; Cooper GS
Cancer; 2012 Sep; 118(18):4404-11. PubMed ID: 22707430
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.
Naber SK; Knudsen AB; Zauber AG; Rutter CM; Fischer SE; Pabiniak CJ; Soto B; Kuntz KM; Lansdorp-Vogelaar I
PLoS One; 2019; 14(9):e0220234. PubMed ID: 31483796
[TBL] [Abstract][Full Text] [Related]
15. Trends and inequities in colorectal cancer screening participation in Ontario, Canada, 2005-2011.
Honein-AbouHaidar GN; Baxter NN; Moineddin R; Urbach DR; Rabeneck L; Bierman AS
Cancer Epidemiol; 2013 Dec; 37(6):946-56. PubMed ID: 23702337
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.
Arrospide A; Idigoras I; Mar J; de Koning H; van der Meulen M; Soto-Gordoa M; Martinez-Llorente JM; Portillo I; Arana-Arri E; Ibarrondo O; Lansdorp-Vogelaar I
BMC Cancer; 2018 Apr; 18(1):464. PubMed ID: 29695234
[TBL] [Abstract][Full Text] [Related]
17. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment.
Vogelaar I; van Ballegooijen M; Schrag D; Boer R; Winawer SJ; Habbema JD; Zauber AG
Cancer; 2006 Oct; 107(7):1624-33. PubMed ID: 16933324
[TBL] [Abstract][Full Text] [Related]
18. Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials.
Lew JB; Greuter MJE; Caruana M; He E; Worthington J; St John DJ; Macrae FA; Feletto E; Coupé VMH; Canfell K
Med Decis Making; 2020 Aug; 40(6):815-829. PubMed ID: 32845232
[No Abstract] [Full Text] [Related]
19. The value of colonoscopic colorectal cancer screening of adults aged 50 to 64.
Fitch K; Pyenson B; Blumen H; Weisman T; Small A
Am J Manag Care; 2015 Jul; 21(7):e430-8. PubMed ID: 26295271
[TBL] [Abstract][Full Text] [Related]
20. Is the type of Medicare insurance associated with colorectal cancer screening prevalence and selection of screening strategy?
Schneider EC; Rosenthal M; Gatsonis CG; Zheng J; Epstein AM
Med Care; 2008 Sep; 46(9 Suppl 1):S84-90. PubMed ID: 18725838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
